



October 23, 2017

Osiris Announces a Peer-Reviewed Publication of a Scientific Study Reporting Antimicrobial Properties of Human Cryopreserved Viable Amniotic Membrane

COLUMBIA, Md., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today a scientific publication of "Antimicrobial Peptides Secreted From Human Cryopreserved Viable Amniotic Membrane Contribute to its Antibacterial Activity" study in a peer-reviewed journal *Scientific Reports* [online](#).

This scientific study was a collaborative effort of scientists from the New Jersey Center for Biomaterials (NJCBM) at Rutgers, The State University of New Jersey in the laboratory of Professor Joachim Kohn and Osiris Therapeutics. Results show inhibitory effects of human cryopreserved viable amniotic membrane (hCVAM) against *P. aeruginosa* and *S. aureus*, both methicillin sensitive (MSSA) and resistant (MRSA) strains. This study also demonstrates the presence of antimicrobial peptides in hCVAM and a correlation with growth inhibition of *P. aeruginosa*, a pathogen commonly found in chronic wounds.

"As important players of the innate immune system, antimicrobial peptides target a broad spectrum of microorganisms via multiple mechanisms of action. Like other components and properties of native placental tissues, antimicrobial peptides and antimicrobial activity are retained in hCVAM. It may provide an additional benefit of applying hCVAM to chronic wounds," said Dr. Yong Mao, Assistant Research Professor at the New Jersey Center for Biomaterials at Rutgers and lead investigator of this study.

"I am very impressed by this important finding, and pleased with the excellent collaboration between Dr. Mao and her colleagues at Osiris that made this possible," added Dr. Kohn, Director of NJCBM. "The results can have a profound impact on solving the problem that chronic wounds present in the field of medicine."

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix®, BIO⁴® (available exclusively through Stryker), and Cartiform® (available exclusively through Arthrex). Osiris, Grafix, Stravix and Cartiform are registered trademarks of Osiris Therapeutics, Inc., and BIO⁴ is a registered trademark of Howmedica Osteonics Corp. Osiris makes no claims concerning functional activities of Grafix or Stravix. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. More information can be found on the Company's website, www.Osiris.com. (OSIR-G)

About the New Jersey Center for Biomaterials (NJCBM)

Founded in 1997 at Rutgers, The State University of New Jersey, the New Jersey Center for Biomaterials Center works to improve health care and quality of life by developing advanced biomedical products for tissue repair and replacement as well as the delivery of pharmaceutical agents. Staffed by biomaterial scientists, NJCBM spans academia, industry, and government, and its technologies have been translated into clinical and pre-clinical products including surgical meshes, cardiovascular stents, bone regeneration scaffolds, and ocular drug delivery systems. www.njbiomaterials.org

About Rutgers, The State University of New Jersey

Rutgers, The State University of New Jersey, is a leading national research university and the state of New Jersey's preeminent, comprehensive public institution of higher education. Established in 1766, the university is the eighth oldest higher education institution in the United States. Nearly 69,000 students and 22,000 full- and part-time faculty and staff learn, work, and serve the public at Rutgers locations across New Jersey and around the world. The university belongs to the Big Ten Academic Alliance, comprised of 14 world-class research universities, and is among the top 20 public U.S. universities for total R&D funding. Rutgers University-New Brunswick is the state's only public institution in the prestigious Association of American Universities.

As the premier public research university in the state, Rutgers is dedicated to teaching that meets the highest standards of excellence, to conducting cutting-edge research that breaks new ground and aids the state's economy, businesses, and industries, and to providing services, solutions, and clinical care that help individuals and the local, national, and global communities where they live. red.rutgers.edu

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as "anticipate," "believe," "continue," "ongoing," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project" or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of products or services and the likelihood of customer clinical adoption of new services. Although well characterized in scientific literature and studies, preservation of tissue integrity including cells may not be indicative of clinical outcome. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events

For additional information, please contact:

Diane Savoie
Osiris Therapeutics, Inc.
(443) 545-1834
OsirisPR@Osiris.com

 Primary Logo

Source: Osiris Therapeutics, Inc.

News Provided by Acquire Media